Advanced Cell Technology, Inc.  

(Public, OTCMKTS:ACTC)   Watch this stock  
Find more results for ACTC
-0.10 (-1.39%)
Oct 20 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 6.91 - 7.25
52 week 4.95 - 12.73
Open 7.15
Vol / Avg. 83,424.00/320,688.00
Mkt cap 242.21M
P/E     -
Div/yield     -
EPS -1.59
Shares 34.21M
Beta 1.00
Inst. own 0%

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -39315.89% -13788.28%
Operating margin -42515.91% -13394.54%
EBITD margin - -10394.14%
Return on average assets -1113.50% -500.18%
Return on average equity - -
Employees 38 -
CDP Score - -


United States - Map
+1-508-7561212 (Phone)
+1-310-5760662 (Fax)

Website links


Advanced Cell Technology, Inc. is a biotechnology company focused on developing and commercializing human embryonic and adult stem cell technology in the emerging field of regenerative medicine. The Company has acquired, developed and maintained a portfolio of patents and patent applications that forms the base for its research and development efforts in the area of embryonic and adult stem cell research. The Company�s emerging field of treatment called regenerative medicine or cell therapy refers to treatments that are founded on the concept of producing new cells to replace malfunctioning or damaged cells as a vehicle to treat disease and injury. It focuses on the development of effective methods to generate replacement cells from both human embryonic and adult stem cells. In September 2011, it received approval from U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to conduct an SMD clinical trial in the United Kingdom.

Officers and directors

Michael T. Heffernan Chairman of the Board
Age: 49
Paul K. Wotton Ph.D. President, Chief Executive Officer, Director
Age: 53
Edward H. Myles CPA Chief Financial Officer, Executive Vice President - Corporate Development
Age: 42
Eddy Anglade M.D. Executive Vice President - Clinical Development
Age: 52
LeRoux Jooste Senior Vice President - Business Development, Chief Commercial Officer
Robert P. Lanza M.D. Chief Scientific Officer
Age: 58
Robert S. Langer Independent Director
Age: 65
Zohar Loshitzer Independent Director
Age: 56
Gregory D. Perry Independent Director
Age: 54
Alan C. Shapiro Ph.D. Independent Director
Age: 68